PubMed Health⌕ Search

Biomedical subjects

H A Körst

Publications and source records attributed to H A Körst.

10 recordsLinked to original sources
PubMed1982

[Sugar-free diet as long-term or interval treatment in the remission phase of Crohn disease--a prospective study].

20 patients with Crohn's disease were entered into a prospective study, after they had been submitted to standard treatment of the acute phase. In this study long term treatment or treatment between the acute relapses of the disease consisted in daily doses of 8 mg methylprednisolone and 3 mg salazosulfapyridine; in addition the diet was sugar-free and rich in fibers. When remission continued (activity index below 150 point) the drugs were stopped and only dietary treatment was continued. The course of the disease was followed by frequent endoscopic examinations and by determinations of the activity index according to Best. 16 patients were in remission after an average treatment period of 19.6+/-6.6 months without drugs only using the dietary regimen described. 4 cases relapsed after 7.5+/-4.3 months (activity index greater tha 150 points, intestinal ulcerations); they had to be treated again according to the acute phase standard treatment schedule. These results encourage further trials, where after 6 months of drug treatment the drugs are stopped, and only dietary treatment is continued during the remission phase.

Adult↗
PubMed1981

[Beware: propafenon potentiates the effect of oral anticoagulants].

In a 68 years old female patient with premature ventricular contractions who was treated with phenprocoumon (Marcumar) because of pulmonary infarction, propafenon (Rytmonorm)--a new anti-arrhythmic drug--lead to an increased effect of coumarin. Inspite of pausing with coumarin for eight days the low Quick rates (less than 15%) did not increase until propafenon was stopped. Afterwards the coumarin treatment was continued with 1,5 to 3 mg a day. In case of a combined treatment with propafenon and coumarin Quick rates should be controlled frequently.

Aged↗
PubMed1981

ERCP: Complications and prophylaxis a controlled study.

Prophylactic measures for the prevention of complications (pancreatitis, pancreatic and biliary sepsis) after an ERCP examination were investigated in a controlled study. A total of 118 patients were selected at random and divided into three groups by post-ERCP treatment (Group A: no treatment, Group B: oral prophylaxis with broad spectrum tetracycline, Group C: bedrest for 36 hours, fasting, stomach catheter and infusion prophylaxis. The total rate of complications in the study as a whole was 5% (2.5% pancreatitis, 2.5% bacterial complications). Statistical comparison of the groups produced no significant differences, i.e. neither the antibiotic nor the infusion prophylaxis proved advantageous with respect to the frequency of pancreatitis and bacterial complications. In addition to this, prophylactic measures after ERCP had no influence on the frequency, duration and extent of such temporary symptoms as abdominal discomfort, fever, leukocytosis, hyperamylasemia, hyperamylasuria and cholestasis. It is worth considering carrying out ERCP on an out-patient basis in special cases.

Amylases↗
PubMed1981

[Atenolol in the treatment of premature ventricular contractions. A double blind study in 68 patients (author's transl)].

The effects of atenolol, a cardioselective beta-blocker, on premature ventricular contractions (PVC) were tested in 68 patients in a double blind trial. 35 patients received 100 mg atenolol p.o/day for 5 days, 33 patients received placebo. A computer-based monitoring system permitted an accurate count of all PVC over a 10-hours pre-drug period and after a 5-days treatment. In both groups there was a significant reduction in PVC frequency, but there was no significant difference between the atenolol group and the placebo group. 45 of 68 patients had a coronary heart disease as cause of PVC, 22 patients in the atenolol group and 23 patients in the placebo group. The statistical examination of those patients only showed results different from the total group. In the atenolol group there was a significant reduction in PVC frequency, average reduction 85% (p less than 0.001). The reduction of PVC frequency inthe atenolol was significantly greater than in the placebo group (p = 0.009). There was a significant reduction in systolic blood pressure and heart rate in the atenolol group, too. Atenolol is an alternative drug in the treatment of PVC in patients with coronary heart disease. The reduction of blood pressure and anginal attacks is an advantage over other conventional antiarrhythmic drugs.

Adrenergic beta-Antagonists↗